Cartesian Therapeutics (RNAC) Tax Rate (2021 - 2022)
Cartesian Therapeutics (RNAC) posted quarterly Tax Rate of 5.14% for Q4 2022, down 625.0% year-over-year from 0.98% in Q4 2021, and down 231.48% quarter-over-quarter from 3.91% in Q3 2022.
Cartesian Therapeutics (RNAC) Tax Rate (2021 - 2022) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Tax Rate for 2 consecutive years, with 5.14% the latest figure, recorded in Q4 2022.
- In Q4 2022, Tax Rate fell 625.0% year-over-year to 5.14%; the TTM figure through Dec 2022 stood at 73.75% (down 65763.0% YoY), while the FY2025 annual figure was 6.6%, up 698.0% from the prior year.
- Tax Rate declined to 5.14% in Q4 2022 per RNAC's latest filing, from 3.91% in the prior quarter.
- Across five years, Tax Rate topped out at 3.91% in Q3 2022 and bottomed at 766.12% in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Tax Rate (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.98% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 15.11% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.91% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 24.15% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -9.47% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 7.49% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.71% |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -5.14% |
| Dec 31, 2022 | -5.14% |
| Dec 31, 2022 | -5.14% |
| Sep 30, 2022 | 3.91% |
| Sep 30, 2022 | 3.91% |
| Sep 30, 2022 | 3.91% |
| Dec 31, 2021 | 1.11% |
| Dec 31, 2021 | 1.11% |
| Dec 31, 2021 | 1.11% |
| Sep 30, 2021 | -766.12% |
| Sep 30, 2021 | -766.12% |
| Sep 30, 2021 | -766.12% |